panickers. Relax everybody, they are simply doing a debt offering to finance the repayment of the existing convertible issue. Why not simply do a debt offering? Because they believe that the convertibles this time around will be converted as Exubera ramps up, and won't ever have to payback the principle. Why not simply do a stock offering? Because this way they get the price of the offering higher, maybe much higher. Some of the major panickers on here are spouting off about toxics and things like that. Well, companies with 300 million plus in cash, and about to bring a major drug to market don't do toxics. This is simply a refiancing, nothing more, nothing less. So relax everyone, and buy some more if you can.